The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for antibiotic-resistant acne being studied in Phase II trials.

Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance and are based on its patented dual action rational therapeutics (DARTs) technology.